CARSGEN-B's stock price fell sharply intraday, declining by 5.04%. The movement represents a continuation of a downward trend following a significant rally earlier in the week.

Market analysis indicates the decline is primarily driven by profit-taking activity. The stock had previously surged over 10% intraday after the company's satri-cel (Shurui Jiaorunsei injection) research results were published in the prestigious medical journal The Lancet. This positive catalyst, representing a breakthrough in solid tumor CAR-T therapy, was fully priced into the stock, leading to a classic "buy the rumor, sell the news" pattern as investors locked in gains.